Patents by Inventor Lawrence Evans

Lawrence Evans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • April and BAFF inhibitory immunomodulatory proteins and methods of use thereof
    Patent number: 12612447
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Grant
    Filed: March 17, 2023
    Date of Patent: April 28, 2026
    Assignee: ALPINE IMMUNE SCIENCES, INC.
    Inventors: Stacey Dillon, Mark Rixon, Lawrence Evans, Daniel William Demonte, Joseph L. Kuijper, Stanford L. Peng
  • CTLA-4 variant immunomodulatory proteins and uses thereof
    Patent number: 12612446
    Abstract: Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.
    Type: Grant
    Filed: January 30, 2023
    Date of Patent: April 28, 2026
    Assignee: Alpine Immune Sciences, Inc.
    Inventors: Lawrence Evans, Joseph L Kuijper, Ryan Swanson
  • CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
    Publication number: 20250320272
    Abstract: Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.
    Type: Application
    Filed: June 26, 2025
    Publication date: October 16, 2025
    Inventors: Lawrence Evans, Joseph L. Kuijper, Ryan Swanson
  • CTLA-4 variant immunomodulatory proteins and uses thereof
    Patent number: 12358969
    Abstract: Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.
    Type: Grant
    Filed: July 20, 2023
    Date of Patent: July 15, 2025
    Assignee: Alpine Immune Sciences, Inc.
    Inventors: Lawrence Evans, Joseph L. Kuijper, Ryan Swanson
  • APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
    Patent number: 12202882
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: January 21, 2025
    Assignee: ALPINE IMMUNE SCIENCES, INC.
    Inventors: Stacey Dillon, Mark Rixon, Lawrence Evans, Daniel William Demonte, Joseph L. Kuijper, Stanford L. Peng
  • APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20250019412
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Application
    Filed: September 24, 2024
    Publication date: January 16, 2025
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG
  • APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20250019413
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Application
    Filed: September 24, 2024
    Publication date: January 16, 2025
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG
  • APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20240400643
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Application
    Filed: August 16, 2024
    Publication date: December 5, 2024
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG
  • APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20240218045
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Application
    Filed: March 17, 2023
    Publication date: July 4, 2024
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG
  • CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
    Publication number: 20240158463
    Abstract: Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.
    Type: Application
    Filed: July 20, 2023
    Publication date: May 16, 2024
    Inventors: Lawrence EVANS, Joseph L. KUIJPER, Ryan SWANSON
  • CTLA-4 variant immunomodulatory proteins and uses thereof
    Patent number: 11753458
    Abstract: Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: September 12, 2023
    Assignee: Alpine Immune Sciences, Inc.
    Inventors: Lawrence Evans, Joseph L. Kuijper, Ryan Swanson
  • CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
    Publication number: 20230250152
    Abstract: Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.
    Type: Application
    Filed: January 30, 2023
    Publication date: August 10, 2023
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Lawrence EVANS, Joseph L. Kuijper, Ryan Swanson
  • APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS WITH AND WITHOUT A T CELL INHIBITORY PROTEIN AND METHODS OF USE THEREOF
    Publication number: 20230241168
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers) alone, or also coupled with inhibition of T cell costimulation. The immunomodulatory proteins provided herein include variant domains of B cell maturation antigen (BCMA) alone, or multi-domain immunomodulatory protein that inhibit B cell responses and also can inhibit T cell costimulation. Also provided are nucleic acids molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Application
    Filed: May 7, 2021
    Publication date: August 3, 2023
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG, Ryan SWANSON
  • VARIANT ICOS LIGAND IMMUNOMODULATORY PROTEINS AND RELATED COMPOSITIONS AND METHODS
    Publication number: 20230235012
    Abstract: Provided herein are immunomodulatory proteins comprising ICOSL variants and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
    Type: Application
    Filed: February 21, 2023
    Publication date: July 27, 2023
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Lawrence Evans, Michael Kornacker, Ryan Swanson
  • Variant ICOS ligand immunomodulatory proteins and related compositions and methods
    Patent number: 11613566
    Abstract: Provided herein are immunomodulatory proteins comprising ICOSL variants and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: March 28, 2023
    Assignee: Alpine Immune Sciences, Inc.
    Inventors: Lawrence Evans, Michael Kornacker, Ryan Swanson
  • VARIANT ICOS LIGAND IMMUNOMODULATORY PROTEINS AND RELATED COMPOSITIONS AND METHODS
    Publication number: 20220112265
    Abstract: Provided herein are immunomodulatory proteins comprising ICOSL variants and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Lawrence EVANS, Michael KORNACKER, Ryan SWANSON
  • APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
    Patent number: 11274140
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: March 15, 2022
    Assignee: Alpine Immune Sciences, Inc.
    Inventors: Stacey Dillon, Mark Rixon, Lawrence Evans, Daniel William Demonte, Joseph L. Kuijper, Stanford L. Peng
  • APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20210388054
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Application
    Filed: May 7, 2021
    Publication date: December 16, 2021
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG
  • APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20210363223
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Application
    Filed: June 11, 2021
    Publication date: November 25, 2021
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG
  • CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
    Publication number: 20200308249
    Abstract: Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.
    Type: Application
    Filed: October 9, 2018
    Publication date: October 1, 2020
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Lawrence EVANS, Joseph L. KUIJPER, Ryan SWANSON